Biomarker Programs

Keith is a board-certified anatomic pathologist with diverse achievements in research and drug/diagnostic development. Leading Ultivue’s Assay Services Laboratory, he brings expertise in investigative pathology, multiplex microscopy and imaging, and digital pathology to our customers striving to realize the promise of personalized medicine. Most recently he was Senior Medical Director of Leica Biosystems, and prior to that he led and supported R&D, toxicology, biomarker, and clinical study teams in multiple therapeutic areas at Novartis and Biogen.

He earned a BS in Chemical Engineering from the University of Arizona, and MD and PhD in Molecular Biology from UCLA, where he discovered the molecular basis of DNA recognition by bHLH-PAS transcription factors. Following residency and postdoc at Stanford, his lab at UT Southwestern characterized the Naked cuticle (Nkd) gene family as feedback regulators of Wnt-beta catenin signaling.

Barry Lynch has been Vice President of Sales since September 2020. He has significant leadership experience across a broad range of life science businesses, including histology, proteomics and diagnostics. Prior to joining Ultivue he was the Commercial Director (EMEA) with Advanced Cell Diagnostics. Barry began his career with Invitrogen in 1999 where he went on to lead commercial teams at the Europe and Asia Pacific regional level. He holds and honors degree in Biochemistry from the University of Dundee and a MSc in Biotechnology.

Mark Rees, PhD joined Ultivue’s executive team in January as Vice President of Corporate Development. Mark has 21+ years of leadership experience in Scientific Affairs and Business development within research and diagnostic markets. Most recently, Mark was instrumental in creating a diagnostic division for StatLab, launching a full portfolio of IHC reagents, automated staining platform as well as a patented reference standard control technology for tissue pathology. Previously Mark held leadership roles in commercial development, Scientific Affairs and R&D at Enzo Lifesciences, Leica Biosystems NA (Danaher) and Novocastra Laboratories.

He holds a PhD in Molecular Biology & Microbiology, MS in Industrial Microbiology and a BS (hons) in Biochemistry, graduating from Newcastle University Medical School, England UK

Anna Pevzner is a Controller and Senior Director of Financial Planning & Analysis at Ultivue.  Anna has nearly 20 years of finance experience in various positions across life sciences, technology, and advanced materials industries in public and venture capital-backed companies.  Most recently Anna led finance function at Veloxint, where she supported fundraising and oversaw planning and accounting for the MIT-incubated advanced materials startup.  Prior to Veloxint Anna was a Director of Financial Planning & Analysis at Syneos Health.  Earlier in her career she held positions of increasing responsibility, including financial planning and analysis, manufacturing finance and accounting at Dolby Laboratories, Thermo Fisher Scientific and Pelephone Communications.

Anna holds an MBA degree from Carnegie Mellon University, Tepper School of Business and BA degree in Economics from Ben-Gurion University of the Negev.